Introduction:
Hepatocellular carcinoma (HCC) is the fifth most common solid tumor worldwide and remains a difficult malignancy to treat (1) . Major obstacles hindering effective treatment for HCC include high recurrence after curative resection, underlying cirrhotic liver, and importantly the frequent resistance of advanced HCC to conventional chemotherapy and radiotherapy (2) . The fact that most patients with advanced HCC do not respond well to current chemotherapeutic agents highlights the need for the development of novel targeted therapy for HCC (3) . And, the promising trial result demonstrated by the multikinase inhibitor sorafenib in patients with advanced HCC demonstrated the potential of molecular targeted therapy for advanced HCC (4) .
Targeting apoptotic pathway is the foundation of many anti-cancer strategies. Among the possibilities, the pathway involving tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is currently the most promising as preclinical models suggest that apoptosis of tumor cells is achievable in vivo without lethal toxicities (5) .
TRAIL is a type II transmembrane protein that belongs to the TNF superfamily and functions through binding to death receptors (DRs) (6) . Currently five DRs that can be subdivided into two distinctive functional groups are known to bind to TRAIL (7, 8) .
DR4 (TRAIL-R1) and DR5 (TRAIL-R2) contain an effective cytoplasmic death domain that forms death-inducing signaling complex (DISC) upon ligand binding and transduce proapoptotic signals (7, 8) CS-1008, a novel humanized agonistic anti-human DR5 antibody, was modified from a murine anti-human DR5 mAb, TRA-8 (9) . CS-1008 has shown selective cytotoxicity towards tumor cells expressing DR5, such as colorectal adenocarcinoma cells, non-small-cell lung cancer cells, pancreatic carcinoma cells, and renal cell adenocarcinoma and has demonstrated enhanced antitumor activity when in combination with gemcitabine or docetaxel (9) . In a phase I trial, CS-1008 exerted no dose limiting toxicity at doses of up to 8 mg/kg weekly (10) . CS-1008 is currently undergoing phase II trials in combination with sorafenib for the treatment of advanced HCC (NCI clinical trial: NCT01033240).
Despite reports of selective TRAIL-induced apoptosis in several types of tumor cells, many cancer cells are resistant to apoptosis induction by TRAIL and more and more evidence suggest that TRAIL alone may not be sufficient to efficiently induce apoptosis in many types of cancers, including HCC (11) (12) (13) (14) . Therefore, it is important both to understand the mechanisms underlying resistance and improve the potency of TRAIL-based therapeutic approaches if TRAIL is going to be successfully used for cancer therapy. Proteasome inhibitors (PIs) represent a highly promising class of anticancer agents to overcome TRAIL resistance or re-sensitize tumors to the apoptotic effect of TRAIL.
Bortezomib is the first PI to be approved clinically for multiple myeloma and mantel cell lymphoma (15, 16) . Bortezomib demonstrated excellent anti-tumor activity against these two hematologic malignancies through blocking proteasome degradation of IκB, an inhibitor of NF-κB (16) . The fact that multiple cellular targets are affected by bortezomib suggests its potential advantage in enhancing antitumor activities in combination treatment with TRAIL in HCC. Indeed, in our previous study exploring the antitumor activity of bortezomib against HCC cells (17) , we showed that down-regulation of p-Akt determines bortezomib's sensitivity, and that bortezomib-induced apoptosis may not be associated with proteasome inhibition in HCC cells. Moreover, we confirmed that bortezomib sensitized HCC cells to TRAIL through inhibition of p-Akt (14) . Importantly, we found that protein phosphatase 2A (PP2A), a phosphatase which down-regulates p-Akt, may mediate the effect of bortezomib on TRAIL sensitization. (14) . The mechanism by which bortezomib upregulates PP2A and in turn down-regulates p-Akt was further delineated in our recent study on the synergistic interaction between bortezomib and sorafenib in HCC cells (18) .
PP2A is a complex of serine/threonine protein phosphatase with broad substrate specificity and diverse cellular functions and consists of a dimeric core enzyme comprising of structural A and catalytic C subunits (the AC core enzyme), and heterogeneous regulatory B subunits (19, 20) . It is known that there are several cellular inhibitors of PP2A, including SET (21) and cancerous inhibitor of PP2A (CIP2A) (22) . Notably, CIP2A (KIAA1524, P90), first cloned from patients with HCC (23), has been shown to promote anchorage-independent cell growth and in vivo tumor formation by inhibiting PP2A activity toward c-Myc (22) . Moreover, CIP2A is over-expressed in HCC and several other human malignancies (22, 24, 25) and is associated with clinical aggressiveness in human breast cancer (24) , suggesting its role as an oncoprotein.
In this study, we found that bortezomib sensitizes TRAIL-resistant HCC cells to CS-1008 through the mediator CIP2A. We demonstrated that CIP2A, through Gene knockdown using siRNA. Smartpool siRNA reagents, including a control (D-001810-10), and CIP2A (L-014135-01) were all purchased from Dharmacon (Chicago, IL) and used according to the procedure described previously (17) . Briefly, cells were transfected with siRNA (final concentration, 100 nM) in 6-well plates using the Dharma-FECT4 transfection reagent (Dharmacon, Chicago, IL) according to the manufacturer's instructions. After 48 hours, the medium was replaced and the HCC cells were incubated with bortezomib, harvested, and separated for western blot analysis and for apoptosis analysis by flow cytometry as described previously (17) . Co-immunoprecipitation assay. Cells were harvested and lysed on ice for 30 minutes in lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM Na 3 VO 4 , 5 mM sodium pyrophosphate, and a protease inhibitor tablet).
The cell lysates were centrifuged at 14,000 × g for 15 minutes, and the supernatants were recovered. Supernatants containing equal amounts of proteins were incubated with 2.5 mg of primary antibodies overnight at 4°C. The immunoprecipitates were harvested using protein G PLUS-agarose beads (Santa Cruz Biotechnology) that were washed once with regular washing buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40), twice with high salt washing buffer (50 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40), and once again with regular washing buffer. Immunoprecipitates were then eluted by boiling the beads for 5 minutes in SDS/PAGE sample buffer and characterized by western blotting with appropriate antibodies.
PP2A phosphatase activity. The protein phosphatase activity in total cellular lysate was determined by measuring the generation of free phosphate from threonine phosphopeptide using the malachite green-phosphate complex assay as described by the manufacturer (Upstate Biotechnology, Lake Placid, NY). Cell lysates were prepared in a low-detergent lysis buffer (1% Nonidet P-40, 10 mM HEPES, 150 mM NaCl, 10% glycerol, 1 mM PMSF, 5 mM benzamidine, and 10 g/mL leupeptin). The phosphatase assay was performed in a PP2A-specific reaction buffer (Upstate) containing 750 μM phosphopeptide substrate. After 10 minutes of incubation at 30°C, the malachite dye was added, and free phosphate was measured by optical density at 650 nm. To avoid variability due to differences in the amounts of immunoprecipitated protein between samples, the phosphatase activities were normalized to the amount of (Fig. 1B) .
We further examined these apoptotic effects using an ELISA kit which detects DNA fragmentation. Our data showed that combination of CS-1008 and bortezomib increased DNA fragmentation in a dose-and time-dependent manner (Fig. 1C) Evidence for the association between CIP2A inhibition and apoptosis induction was further strengthened by the time-dependent PARP cleavage in the combined bortezomib and CS-1008 treated HCC cells (Fig. 2B) . These results suggest that inhibition of CIP2A plays a key role in the mediating effects of the drug combination.
Target validation of CIP2A. Two different approaches were used to validate the role of CIP2A in the sensitizing effect of bortezomib on CS-1008 induced apoptosis in HCC cells. First, we knocked down protein expression of CIP2A by using small interference RNA (siRNA). Sk-Hep1 cells were transfected with either scrambled siRNA as a control or CIP2A siRNA for 48 hours and were then exposed to DMSO or CS-1008 (200 ng/ml) for another 24 hours. As shown in Fig. 3A effect of CIP2A on P-Akt. Next, we generated Sk-Hep1 (CIP2A-myc) cells with stably expressed CIP2A to investigate the sensitizing effect of bortezomib. Ectopic expression of CIP2A significantly abolished the sensitizing effect of bortezomib on CS-1008-induced apoptosis, in comparison with wild-type Sk-Hep1 cells that underwent the same treatment (P < 0.05) (Fig 3B) . Together, these results validated the importance of CIP2A inhibition in mediating the effect of bortezomib on CS-1008 sensitivity to HCC cells.
CIP2A inhibits Akt-associated PP2A activity. Our previous work demonstrated that bortezomib increased PP2A activity in HCC cells (14, 18) . We, thus, next examined how bortezomib and CS-1008 combination treatment affected PP2A activity. As shown in Figure 4A , bortezomib plus CS-1008 significantly up-regulated PP2A activity in Sk-Hep1 and Huh-7 cells. Moreover, we found that treatment with either of the drugs alone or in combination did not significantly affect the protein level of PP2A complex including subunit A, B56γ and C in Sk-Hep1 and Hep3B cells, except the drugs combination decreased PP2A-B55y in Huh-7 cells (Fig. 4B) . These data suggested that the alterations of PP2A complex may not play a major role in mediating the sensitizing effect of bortezomib on CS-1008-treated HCC cells. Notably, CS-1008 and bortezomib combination treatment, compared with either drug alone, did not alter protein-protein interactions between Akt and PP2A significantly, suggesting that CIP2A does not affect their binding affinity directly (Fig. 4C) . In addition, previous study has indicated that CIP2A inhibits c-myc-associated PP2A activity thereby stabilizing c-myc (22) . We, therefore, similarly examined Akt-related PP2A activity by co-immunoprecipitation of Akt in Sk-Hep1 cells. Our data indicated that ectopic expression of CIP2A reduced PP2A activity on Akt, suggesting that CIP2A plays a role in regulating Akt-related PP2A activity (Fig. 4D, left) . In addition, the data of immunofluoresence staining also showed that the CIP2A-myc cells had higher P-Akt than the wild type cells (Fig. 4D, right) . The treatment of okadaic acid (a PP2A inhibitor) in wild type cells enhanced the expression of P-Akt whereas forskolin (a PP2A agonist) reduced the expression of P-Akt in CIP2A-myc cells (Fig. 4D, right) .
These data indicate that CIP2A reduces the PP2A activity on Akt in HCC cells. (Fig. 5C) showed a significant increase in PP2A phosphatase activity (P < 0.05) in Huh-7 tumors treated with bortezomib alone and bortezomib plus CS-1008. However, the treatment of CS-1008 alone did not show significant effects on CIP2A and the PP2A activity (versus control, P ＞ 0.05), which is consistent with previous in vitro findings ( Fig. 2A & 3A) . These data indicate mediation of the effect via 
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PP2A-dependent Akt inactivation in vivo.
Further clinical investigation is warranted.
Discussion:
In this study, we confirmed that CS-1008, a novel anti-human DR5 antibody with promising TRAIL-like anti-cancer activity, is not sufficient to kill HCC cells as a monotherapy. However, we found that bortezomib effectively sensitizes HCC cells to this novel anti-DR5 antibody. Importantly, we delineated the mechanism by which bortezomib sensitizes these resistant cells to CS-1008. Our results have several important implications. First, CIP2A may serve as a potential drug target in HCC. We identified CIP2A inhibition as a major determinant of bortezomib's sensitizing effects which is dissociated from proteasome inhibition. This suggests that other novel agents that are capable of down-regulating CIP2A protein expression may also be good sensitizers of TRAIL resistant cells. Indeed, knockdown of CIP2A by siRNA was able to restore CS-1008 induced apoptosis in resistant Sk-Hep1 cells ( Figure 3A) .
Moreover, Sk-Hep1 cells with ectopic over-expression of CIP2A were more resistant to the effect of bortezomib and CS-1008 combination treatment ( Figure 3B) . As an oncoprotein CIP2A may promote cancer cell aggressiveness, thereby facilitating resistance of cancer cells to apoptotic-inducing agents. Currently there are no known specific CIP2A inhibitors and whether CIP2A is suitable as predictive markers for drug therapy remain to be determined. Future pre-clinical research exploring agents that inhibit CIP2A and clinicopathological studies correlating CIP2A expression and drug-sensitivity in HCC patients are warranted to further consolidate CIP2A as a good drug target. Notably, the data from a phase I study in human indicate that CS-1008 is well tolerated and the C min of CS-1008 is 14 μg/ml (1 mg/kg/week) (26). 
Various mechanisms contribute to TRAIL resistance in cancers (12) . Resistance to TRAIL can occur at any step in the apoptosis signaling cascade. For example, receptor level mutations or overexpression of DR4 or DR5 can lead to resistance (12) .
Defects in members participating in DISC assembly, such as FADD, caspase-8, and cellular FADD-like interleukin-1b-converting enzyme inhibitory protein (cFLIP) can also result in resistance to TRAIL (27, 28) . Furthermore, overexpression of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-XL, Mcl-1, etc) (29, 30) , loss of proaoptotic protein function (Bax or Bak), and an inability to activate mitochondria during apoptosis such as reduced release of mitochondria-derived activator of caspases (Smac/Diablo) have been shown to cause TRAIL resistance in mitochondria dependent type II cancer cells (12, 31) . Finally, aberrantly activated antiapoptotic pathways in various tumor cells, such as phosphoinositol-3-kinase (PI3K)/Akt signaling, mitogen-activated protein kinases pathway and nuclear factor-kappa B (NF-kB) may contribute to development of TRAIL resistance (12, 32, 33) .
Interestingly, we discovered that through CIP2A-PP2A-p-Akt regulatory mechanism, bortezomib overcomes CS-1008 resistance, supporting the hypotheis that constitutively active Akt signaling confers resistance of HCC cells to TRAIL and anti-DR5 CS-1008.
Previous literature including our own work has demonstrated that bortezomib as well as other investigational proteasome inhibitors are capable of sensitizing cancer cells to TRAIL-induced apoptosis (14, (34) (35) (36) (37) (38) . However, the molecular mechanisms underlying the sensitizing effect of bortezomib seem to be complicated and may be specific to cancer types. In certain cancer types, sensitization to TRAIL resistance has been reported to be through proteasome inhibition, including up-regulation of TRAIL receptors (34, 38) , activation of both extrinsic and intrinsic apoptosis pathways (39, we demonstrated that bortezomib is able to sensitize TRAIL resistance by its proteasome inhibition independent effects in TRAIL-resistant HCC cells. Importantly, despite the fact that TRAIL can activate NF-kB (41, 42) and that bortezomib effectively inhibits NF-kB signaling, it seems that in HCC cells, inhibition of NF-kB may not be the major determinant of TRAIL sensitization by bortezomib, as demonstrated by our previous work (14, 17) .
Numerous studies have shown that a combination of chemotherapy and targeted agents can enhance the antitumor activity of TRAIL and its agonists through cross-talk between the intrinsic and extrinsic apoptotic pathways (8) . Among the many novel agents with potential to sensitize or overcome TRAIL resistance, the combination of bortezomib and CS-1008 represents a fascinating strategy for several reasons. Bortezomib is approved for clinical use and exerts particularly tolerable toxicity when combined with other cytotoxic chemotherapeutic agents (such as doxorubicin, melphalan, or vincristine), and even when used in combination with intensive salvage chemotherapy in patients with refractory hematological malignancies (43, 44) . CS-1008, for its part, although still under clinical investigation, has shown an excellent toxicity profile with low hepatic toxicity (9, 10, 45) , which is particularly suitable for patients with HCC. In addition, as CS-1008 is DR5 specific, the potency of CS-1008 may not be affected by problems with DR4 mutations or dysfunction. DR5 mutations have been reported to be infrequent in HCC cells (46) . Sk-Hep1 cells were exposed to bortezomib and/or CS-1008 for the indicated period of time. Cell lysates were prepared and assayed for CIP2A, P-Akt, Akt, and PARP. CF, cleaved form (activated form). 
